3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Ovarian Neoplasms
33
Breast Neoplasms
26
Triple Negative Breast Neoplasms
17
Prostatic Neoplasms
16
Fallopian Tube Neoplasms
11
Neoplasms
9
Fanconi Anemia, Complementation Group D1
7
Endometrial Neoplasms
7
Pancreatic Neoplasms
6
Glioma
6
Carcinoma, Ovarian Epithelial
6
Stomach Neoplasms
5
Small Cell Lung Carcinoma
5
Sarcoma
5
Neoplasm Metastasis
5
Cholangiocarcinoma
5
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Lymphoma, Non-Hodgkin
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Osteosarcoma
3
Lung Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Carcinosarcoma
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Interventions
Fulvestrant
3
Alpelisib
3
parsaclisib
2
Paclitaxel
2
Irinotecan
2
Cetuximab
2
Carboplatin
2
tanezumab
1
talazoparib
1
sotorasib
1
serabelisib
1
sapanisertib
1
ruxolitinib
1
olaparib
1
niraparib
1
liposomal doxorubicin
1
inavolisib
1
dapagliflozin
1
ceralasertib
1
binimetinib
1
berzosertib
1
avelumab
1
Vemurafenib
1
Topotecan
1
Taxes
1
SF 1126
1
Oxaliplatin
1
Lomustine
1
Leuprolide
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hereditary Sensory and Autonomic Neuropathies
×
olaparib
×
Clear all
NCT04038502
2025-08-20
COBRA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled